# How AI Is Improving Breast Cancer Screening — and What It…

> Source: https://breastcancer-charity.org/blog/ai-mammography-improving-breast-cancer-detection/
> Artificial intelligence tools are now reading mammograms alongside radiologists on the NHS. Here is what the evidence shows about accuracy, the cancer…

Artificial intelligence has been a topic of intense research in radiology for years, but in 2023 and 2024 it moved from clinical trials into real-world NHS use. AI tools are now deployed at several NHS breast screening centres, reading mammograms alongside human radiologists. The question is no longer whether AI can analyse a mammogram — it clearly can — but whether it makes the screening programme better for patients.

## What the SYMPLIFY and PROSE trials showed

The SYMPLIFY trial, published in The Lancet Oncology, tested AI as a triage tool for mammograms, prioritising the cases that most needed urgent human review. The PROSE trial went further, evaluating AI as a second reader — replacing the second radiologist who currently reads every NHS mammogram. Results showed that AI-assisted reading was non-inferior to double human reading in cancer detection rate, while significantly reducing radiologist workload. Crucially, the false-positive rate (unnecessary recall) did not increase.

## What this means for the NHS screening programme

The NHS breast screening programme currently invites women aged 50–71 every three years. Every mammogram is read by two radiologists independently — a process designed to catch cancers one reader might miss. AI is being evaluated as a replacement for the second reader, which would release significant radiologist capacity. With radiologist shortages a known challenge for NHS radiology, this has real implications for waiting times and programme coverage.

## What AI cannot yet do

- AI tools are currently validated for mammography only — not for MRI or ultrasound breast screening
- AI performance varies by breast density and by cancer subtype — it remains better at detecting some cancers than others
- Clinical decision-making (biopsy, referral, treatment) remains firmly with human clinicians
- AI tools require ongoing validation as the screening population and imaging technology evolves
- Regulatory approval and NHS-wide rollout are still in progress — AI is not yet standard across all NHS trusts

## The global picture: AI in low-resource settings

For high-income countries, AI offers efficiency gains in an already-functioning system. The more transformative potential may be in low-income communities, where radiologist shortages mean mammograms are simply not read at all. Researchers are exploring whether AI could enable community screening programmes — operating with portable digital mammography units and cloud-based AI reading — in settings where a specialist radiologist is not available. This remains early-stage, but the direction is significant.

Share this article

[Share on X](https://twitter.com/intent/tweet?text=How%20AI%20Is%20Improving%20Breast%20Cancer%20Screening%20%E2%80%94%20and%20What%20It%20Means%20for%20Patients&url=https%3A%2F%2Fbreastcancer-charity.org%2Fblog%2Fai-mammography-improving-breast-cancer-detection%2F) [Facebook](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fbreastcancer-charity.org%2Fblog%2Fai-mammography-improving-breast-cancer-detection%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fbreastcancer-charity.org%2Fblog%2Fai-mammography-improving-breast-cancer-detection%2F)

---
Breast Cancer Charity — an initiative of World Aid Network. Donate: https://breastcancer-charity.org/donate/